Cancer Care Ontario | Cancer Care Ontario

luspatercept - For the treatment of red-blood cell (RBC) transfusion-dependent anemia associated with Myelodysplastic Syndromes (MDS), according to clinical criteria

Show More Show more tags

, Show Less Show fewer tags

Drugs Used:

luspatercept

... Show more tags

, Collapse Show fewer tags

Quick Link(s):

Regimen Monograph

Jul 2025

Document

[PDF]

LungCancerScreening_ReferralForm.pdf

Apr 2021

Guidelines and Advice

Evidence from Primary Studies and Systematic Reviews and Recommendations from Clinical Practice Guidelines July to December 2020

Status: Current
ID: PET 2020-2

May 2021

Lettre de confidentialité de ContrôleCancerColorectal

Regimen

LURB

Cancer Type:

Lung,

Small Cell

Show More Show more tags

, Show Less Show fewer tags

Intent: Palliative

Drugs Used:

lurbinectedin (Unfunded)

... Show more tags

, Collapse Show fewer tags

Quick Link(s):

Regimen Monograph

Nov 2023

Regimen

LARO

Cancer Type:

Breast,

Central Nervous System,

Endocrine,

Adrenal,

Neuroendocrine,

Pancreatic Neuroendocrine,

Parathyroid,

Thymoma,

Thyroid,

Gastrointestinal,

Anus,

Colorectal,

Esophagus,

Gastric / Stomach,

Gastrointestinal Stromal Tumours,

Hepatobiliary / Liver / Bile Duct,

Mesothelioma (Peritoneal),

Neuroendocrine (GI),

Pancreas,

Rectal,

Small bowel and appendix,

Genitourinary,

Bladder / Urothelial,

Penile,

Prostate,

Renal cell / Kidney,

Testis,

Gynecologic,

Cervix,

Endometrial,

Germ Cell,

Gestational Trophoblastic Disease,

Ovary,

Uterine Sarcoma,

Vagina,

Vulva,

Head and Neck,

Larynx,

Nasopharynx,

Oral,

Paranasal Sinus,

Pharynx,

Salivary Gland,

Squamous Cell,

Kaposi's Sarcoma,

Lung,

Mesothelioma (Pleural),

Neuroendocrine (Lung),

Non-Small Cell,

Small Cell,

Sarcoma,

Desmoid Tumour,

Ewing's,

Ewing's and Soft Tissue,

GIST,

Giant Cell Tumour,

Kaposi's Sarcoma,

Osteogenic / Bone,

Soft Tissue,

Uterine,

Wilm's Tumour,

Skin,

Basal Cell,

Melanoma,

Merkel Cell,

Squamous Cell,

Unknown Primary

Show More Show more tags

, Show Less Show fewer tags

Intent: Palliative

Funding:

Exceptional Access Program

larotrectinib - For the treatment of unresectable locally advanced, or metastatic solid tumours with neurotrophic tyrosine receptor kinase (NTRK) gene fusion, according to clinical criteria

Show More Show more tags

, Show Less Show fewer tags

Drugs Used:

larotrectinib

... Show more tags

, Collapse Show fewer tags

Quick Link(s):

Regimen Monograph

Sep 2025

Regimen